Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study

Author:

Ferhanoglu Burhan1ORCID,Kim Tae Min2,Karduss Amado3ORCID,Brittain David4,Tumyan Gayane5,Al-mansour Mubarak67,Zerga Marta8,Song Yuqin9,Rivas-Vera Silvia10,Kwong Yok Lam1112ORCID,Lim Soon Thye13,Yeh Su-Peng14,Abdillah Arif15ORCID,Huang Zhongwen16,Dalal Mehul16ORCID,Wan Hui15,Hertzberg Mark1718

Affiliation:

1. Division of Hematology, Department of Internal Medicine, Koç University School of Medicine, Istanbul, Turkey

2. Department of Internal Medicine, Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul, South Korea

3. Bone Marrow Transplant Program, Instituto de Cancerologia, Clínica las Américas, Medellín, Colombia

4. Albert Alberts Stem Cell Transplant Center, Pretoria East Hospital, Pretoria, South Africa

5. Department of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Russia

6. Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah, The Kingdom of Saudi Arabia

7. College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, The Kingdom of Saudi Arabia

8. Department of Hematology, Angel Roffo Institute, Buenos Aires, Argentina

9. Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China

10. Department of Hematology, Instituto Nacional de Cancerologia Mexico, Mexico City, Mexico

11. Bone Marrow Transplant Unit, Queen Mary Hospital, Hong Kong, China

12. Hematology Division, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, University of Hong Kong, Hong Kong, China

13. Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

14. Division of Hematology and Oncology, Department of Medicine, China Medical University Hospital, Taichung, Taiwan

15. Takeda Pharmaceuticals International AG–Singapore Branch, Singapore, Singapore

16. Takeda R&D Data Sciences Institute, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA

17. Department of Clinical Haematology, Prince of Wales Hospital, Sydney, Australia

18. University of New South Wales, Sydney, Australia

Funder

Takeda Pharmaceuticals International AG–Singapore Branch

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3